I appreciate that.
You made a reference to increased transparency in all the clinical data. I think you went on to talk about making it an offence if a company is convicted of misleading the regulator.
I think we had a pretty egregious example of that back in 2007, of a company, part of Purdue, that I think was charged in the United States with misleading the regulator. There was a fairly hefty fine involved. That would be on the U.S. side, wasn't it? It had to do with OxyContin.
Is that what you're driving at with this?